Navigation Links
Researchers use DNA to build tool that may literally shine light on cancer
Date:5/7/2014

Bioengineers at the University of Rome Tor Vergata and the University of Montreal have used DNA to develop a tool that detects and reacts to chemical changes caused by cancer cells and that may one day be used to deliver drugs to tumor cells.

The researchers' nanosensor measures pH variations at the nanoscale how acidic (a higher pH level) or alkaline (a lower pH level) it is. Many biomolecules, such as enzymes and proteins, are strongly regulated by small pH changes. These changes affect in turn biological activities such as enzyme catalysis, protein assembly, membrane function and cell death. There is also a strong relation between cancer and pH.

Cancer cells often display a lower pH compared to normal cells: the pH level inside cancer cells is higher than it is outside. "In living organisms, these small pH changes typically occur in tiny areas measuring only few hundred nanometers," says senior author Prof. Francesco Ricci. "Developing sensors or nanomachines that can measure pH changes at this scale should prove of utility for several applications in the fields of in-vivo imaging, clinical diagnostics and drug-delivery."

"DNA represents an ideal material to build sensors or nanomachines at the nanometer scale" says senior author Prof. Valle-Blisle. "By taking advantage of a specific DNA sequences that form pH-sensitive triple helix, we have designed a versatile nanosensor that can be programmed to fluoresce only at specific pH values." Fluorescence is the emission of radiation, including visible light, caused by an exchange of energy. "This programming ability represents a key feature for clinical applications we can design a specific sensor to send a fluorescent signal only when the pH reaches a specific value which is, for example, characteristic of a specific disease," adds first author Andrea Idili.

In the future, this recently patented nanotechnology may also find applications in the development of novel drug-delivery platforms that release chemio-therapeutic drugs only in the viscinity of tumor cells.


'/>"/>

Contact: William Raillant-Clark
w.raillant-clark@umontreal.ca
514-566-3813
University of Montreal
Source:Eurekalert  

Related medicine news :

1. Sleep researchers at SRI International identify promising new treatment for narcolepsy
2. Chimpanzees show similar personality traits to humans, Georgia State researchers say
3. Researchers present findings on promising biomarker for esophageal cancer
4. Bioinformatics approach helps researchers find new uses for old drug
5. BrightFocus honors 5 vision researchers
6. Researchers link age, general health and antidepressant use with eye disorders
7. Researchers granted funding to explore novel lung cancer strategies
8. MS researchers find brain & cognitive reserve protect long-term against cognitive decline
9. UNC researchers discover master regulator role for little-known protein in cancer cells
10. CWRU researchers profile womens employment, caregiving workloads, effort and health
11. Drug monitoring information improves regimen adherence, Carnegie Mellon researchers say
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Researchers use DNA to build tool that may literally shine light on cancer
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson has ... he has implemented orthobiologic procedures as a method for treating his patients. The ... first doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons use ...
(Date:6/24/2016)... ... , ... Those who have experienced traumatic events may suffer from a complex ... as drug or alcohol abuse, as a coping mechanism. To avoid this pain and ... a traumatic event. , Trauma sufferers tend to feel a range of emotions, from ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Global law ... magazine’s 2016 Legal Elite. The attorneys chosen by their peers for this recognition are ... , Seven Greenberg Traurig Shareholders received special honors as members of this year’s Legal ...
(Date:6/24/2016)... Plano, TX (PRWEB) , ... June 24, 2016 , ... ... taking part in Genome magazine’s Code Talker Award, an essay contest in which patients ... for an award to be presented at the 2016 National Society of Genetic Counselors ...
(Date:6/24/2016)... ... 2016 , ... Strategic Capital Partners, LLC (SCP) in concert ... capital for emerging technology companies. SCP has delivered investment events and professional ... than a million dollars of capital investment for five companies. The ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... June 23, 2016 Research and ... Excipients Market by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), ... Topical, Coating, Parenteral) - Global Forecast to 2021" ... The global pharmaceutical excipients market is projected ... CAGR of 6.1% in the forecast period 2016 to ...
(Date:6/23/2016)... -- Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that ... PCT (procalcitonin) assay as a dedicated testing solution for ... clearance, Roche is the first IVD company in the ... risk assessment and management. PCT is a ... in blood can aid clinicians in assessing the risk ...
(Date:6/23/2016)... 23, 2016 Capricor Therapeutics, ... a biotechnology company focused on the discovery, development ... patient enrollment in its ongoing randomized HOPE-Duchenne clinical ... 50% of its 24-patient target. Capricor expects the ... quarter of 2016, and to report top line ...
Breaking Medicine Technology: